Stock Monitor: Sonoma Pharma Post Earnings Reporting
LONDON, UK / ACCESSWIRE / February 12, 2018 / Active-Investors.com has just released a free research report on Novo Nordisk A/S (NYSE: NVO). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=NVO as the Company's latest news hit the wire. On February 09, 2018, the Company, which is a global healthcare organization with 95 years of innovation and leadership in diabetes care, declared that the European Commission (EC) has granted marketing authorization for Ozempic (semaglutide) for the treatment of adults with Type 2 diabetes. This marketing authorization is applicable for all 28-member states of the European Union (EU). Register today and get access to over 1000 Free Research Reports by joining our site below:
www.active-investors.com/registration-sg
Active-Investors.com is currently working on the research report for Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA), which also belongs to the Healthcare sector as the Company Novo Nordisk. Do not miss out and become a member today for free to access this upcoming report at:
www.active-investors.com/registration-sg/?symbol=SNOA
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Novo Nordisk A/S most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
www.active-investors.com/registration-sg/?symbol=NVO
Increasing Prevalence of Diabetes in the EU
The prevalence of diabetes is increasing among all age groups in the European Region, mainly due to increases in overweight and obesity, unhealthy diet, and physical inactivity. At present, there are more than 60 million people suffering from diabetes in the European Region.
Globally, high blood glucose kills about 3.4 million people annually. Of these, approximately 80% deaths occur in low- and middle-income countries, and almost half are people below 70 years of age. As per the World Health Organization (WHO)'s projections, diabetes deaths will double between 2005 and 2030.
About Ozempic
Ozempic is a new once-weekly analogue of human glucagon-like peptide-1 (GLP-1) that has been developed for the treatment of Type 2 diabetes. Glucagon is a pancreatic hormone, which counteracts the glucose-lowering action of insulin by stimulating glycogenolysis and gluconeogenesis. It is mostly indicated as monotherapy when metformin is unsuitable due to intolerance or is contra-indicated. Ozempic can also be recommended as an addition to other medicinal products for the treatment of diabetes.
Approval Based on SUSTAIN Trial
This approval of Ozempic is based on the SUSTAIN program, which was a global clinical development program comprising eight Phase-3a trials. It enrolled over 8,000 adults with Type 2 diabetes. The Phase-3a program was conducted with a large number of people with Type 2 diabetes, including some with high cardiovascular risk profiles, and people with and without renal disease.
The EU approval follows the approvals from the US and Canada. The US Food and Drug Administration (FDA) approved Ozempic on December 05, 2017, and Health Canada on January 09, 2018.
Novo Nordisk to Seek Approval of Updated Ozempic Pen Offering
So far, Ozempic has been approved in the EU for use in the form of a multi-dose Ozempic pen. These pens are the latest generation of Novo Nordisk pre-filled devices.
But Novo Nordisk has also created an updated Ozempic pen offering, which helps facilitate reimbursement for patients with type 2 diabetes using Ozempic. The Company intends to submit a variation application to the European Medicines Agency (EMA) in order to seek approval for this new updated pen offering.
Novo Nordisk plans to launch Ozempic in the first EU countries in the second half of 2018, after receiving the approval of the variation application for the updated pen offering.
Ozempic Can Set A New Standard For The Treatment Of Type 2 Diabetes
Treatment with Ozempic can lead to sustained reductions in Glycated hemoglobin (HbA1c) and body weight, as well as cardiovascular benefits, in comparison to existing standard of care for Type 2 diabetes. Besides, Ozempic can also lead to the statistically significant reduction in diabetic nephropathy, i.e. diabetes-related kidney damage.
Mads Krogsgaard Thomsen, the Executive Vice President and Chief Science Officer at Novo Nordisk, expressed his pleasure on the approval of Ozempic in the EU. Thomsen believes Ozempic has the potential to set a new standard for the treatment of Type 2 diabetes. The strong clinical profile of Ozempic could provide a valuable solution for people suffering with Type 2 diabetes.
Stock Performance Snapshot
February 09, 2018 - At Friday's closing bell, Novo Nordisk A/S's stock climbed 3.19%, ending the trading session at $50.07.
Volume traded for the day: 3.54 million shares, which was above the 3-month average volume of 1.32 million shares.
Stock performance in the previous six-month period - up 13.41%; and past twelve-month period - up 45.21%
After last Friday's close, Novo Nordisk A/S's market cap was at $97.25 billion.
Price to Earnings (P/E) ratio was at 19.79.
The stock has a dividend yield of 1.90%.
The stock is part of the Healthcare sector, categorized under the Drug Manufacturers - Other industry. This sector was up 1.1% at the end of the session.
Active-Investors:
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Active-Investors
